KMT2A and acute myeloid leukemia: Potential use of the unrelated menin-MLL1 inhibitor ziftomenib in combination with either the BCL2 inhibitor venetoclax or the BET inhibitor OTX015 is also supported by synergistic cytotoxicity, as recently demonstrated in cells derived from patients with MLLr or NPM1c AML(59).